PREMIER INVESTMENT ADVISORS, INC.’s AbbVie ABBV Stock Holding History

PREMIER INVESTMENT ADVISORS, INC.’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$223K	Buy	+853	New	+$219K	0.39%	35

Other funds holding ABBV

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

PREMIER INVESTMENT ADVISORS, INC.'s ABBV Position: Q3 2026 in Review

PREMIER INVESTMENT ADVISORS, INC. opened a new position in AbbVie (ABBV) in Q3 2026: 853 shares worth $223K. The stake represents 0.39% of the portfolio and ranks #35 among its holdings.

3,450 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

PREMIER INVESTMENT ADVISORS, INC. held 853 shares of AbbVie worth $223K as of Q3 2026.
AbbVie was a new PREMIER INVESTMENT ADVISORS, INC. position in Q3 2026.
AbbVie made up 0.39% of PREMIER INVESTMENT ADVISORS, INC.'s portfolio in Q3 2026, its #35 holding.
3,450 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on PREMIER INVESTMENT ADVISORS, INC.'s 13F filing for Q3 2026, filed 12 Nov 2026.